drugset
drugset / Trial / NCT02273401

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

NCT02273401 ↗

Phase 1 Completed 96 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, and pharmacokinetics of BI 11054

Timeline

Start
2008-01
Primary completion
2008-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 11054 CL Unknown 0.5 ug Inhaled
Subject BI 11054 CL Unknown 70 ug Inhaled

Indications

No indication recorded.